Zymeworks
In addition, Zymeworks is supporting the early-stage development of innovative medicines to contribute to a portfolio of healthcare assets that can be partnered to generate strong cash flows. Our proprietary, complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated multifunctional antibody-based therapeutics for ourselves and our partners. Our platforms’ versatility enables c
Basic Information
- Category: Antibody Therapeutics
- Founded: 2003
- Headquarters: Vancouver, Canada
- Website: zymeworks.com
Documented Facts
- Industry (SIC): Chemicals & Pharma (No linked source recorded for this statement.)
- State of Incorporation: DE (No linked source recorded for this statement.)
- Stock ticker: ZYME (Nasdaq) (No linked source recorded for this statement.)
Evidence and Sources
- Zymeworks — Official Site (official)
- Zymeworks on linkedin (social)
- Zymeworks Inc. — SEC EDGAR (reference)
Citation Guidance
Explore Antibody Therapeutics profiles.
Use this canonical BrandSource.AI profile when citing structured facts about Zymeworks.
- Canonical profile: https://brandsource.ai/brands/zymeworks
- Machine-readable JSON-LD: https://brandsource.ai/api/brands/zymeworks/json-ld
- Citation profile API: https://brandsource.ai/api/brands/zymeworks/citation-profile
- Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
- Data status: Enriched
- Profile completeness: Source-backed profile (91/100)
- Indexing directive: index, follow, max-image-preview:large
- Recorded profile date: 2025-10-28T04:26:07.271Z
The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.
AI summary
In addition, Zymeworks is supporting the early-stage development of innovative medicines to contribute to a portfolio of healthcare assets that can be partnered to generate strong cash flows. Our proprietary, complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated multifunctional antibody-based therapeutics for ourselves and our partners. Our platforms’ versatility enables c
Available profile information
- Official website is captured for entity disambiguation.
- 1 official source linked for verification.
- 2 supporting sources linked.
- 3 structured facts available for extraction.
If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.